Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by AHMED KASEB and HESHAM AMIN.
AHMED KASEB
Connection Strength
6.238
HESHAM AMIN
  1. Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Front Oncol. 2022; 12:986305.
    View in: PubMed
    Score: 0.862
  2. Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma. J Immunother Precis Oncol. 2024 Nov; 7(4):255-262.
    View in: PubMed
    Score: 0.249
  3. Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma. Oncology. 2024 Oct 18; 1-8.
    View in: PubMed
    Score: 0.248
  4. Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report. J Gastrointest Oncol. 2024 Jun 30; 15(3):1324-1330.
    View in: PubMed
    Score: 0.243
  5. Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2024; 11:455-461.
    View in: PubMed
    Score: 0.238
  6. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomark. 2024; 41(1):83-91.
    View in: PubMed
    Score: 0.235
  7. The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Cancers (Basel). 2023 Oct 07; 15(19).
    View in: PubMed
    Score: 0.231
  8. Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology. 2023; 101(11):730-737.
    View in: PubMed
    Score: 0.229
  9. Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma. J Hematol Oncol. 2023 Jun 13; 16(1):61.
    View in: PubMed
    Score: 0.226
  10. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022 12 06; 13:1314-1321.
    View in: PubMed
    Score: 0.218
  11. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. J Hepatocell Carcinoma. 2022; 9:823-837.
    View in: PubMed
    Score: 0.213
  12. HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology. 2021 06; 73(6):2278-2292.
    View in: PubMed
    Score: 0.197
  13. REPLY. Hepatology. 2021 06; 73(6):2612.
    View in: PubMed
    Score: 0.196
  14. REPLY. Hepatology. 2021 06; 73(6):2614.
    View in: PubMed
    Score: 0.196
  15. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget. 2021 Apr 13; 12(8):756-766.
    View in: PubMed
    Score: 0.195
  16. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020; 98(12):836-846.
    View in: PubMed
    Score: 0.188
  17. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study. J Hepatocell Carcinoma. 2020; 7:143-153.
    View in: PubMed
    Score: 0.187
  18. Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget. 2020 Mar 31; 11(13):1186-1201.
    View in: PubMed
    Score: 0.181
  19. Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. J Immunother Cancer. 2019 11 28; 7(1):329.
    View in: PubMed
    Score: 0.177
  20. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118.
    View in: PubMed
    Score: 0.173
  21. Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma. J Hematol Oncol. 2019 07 24; 12(1):80.
    View in: PubMed
    Score: 0.173
  22. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget. 2018 Dec 28; 9(102):37721-37732.
    View in: PubMed
    Score: 0.166
  23. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242.
    View in: PubMed
    Score: 0.150
  24. Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget. 2017 Jan 03; 8(1):1814-1844.
    View in: PubMed
    Score: 0.145
  25. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016 Oct 25; 7(43):69916-69926.
    View in: PubMed
    Score: 0.143
  26. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma. 2015; 2:131-42.
    View in: PubMed
    Score: 0.132
  27. Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. Oncotarget. 2015 Aug 28; 6(25):21193-207.
    View in: PubMed
    Score: 0.132
  28. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK? T-cell lymphoma. Mol Cancer. 2015 Feb 25; 14:53.
    View in: PubMed
    Score: 0.127
  29. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology. 2024 07 01; 80(1):87-101.
    View in: PubMed
    Score: 0.059
  30. Bayesian Edge Regression in Undirected Graphical Models to Characterize Interpatient Heterogeneity in Cancer. J Am Stat Assoc. 2022; 117(538):533-546.
    View in: PubMed
    Score: 0.051
  31. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019 07 15; 129(8):3324-3338.
    View in: PubMed
    Score: 0.043
  32. Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs. Oncology. 2016; 91(2):90-100.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.